Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
GERN's Cash to Debt is ranked higher than
79% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. GERN: No Debt )
GERN' s 10-Year Cash to Debt Range
Min: 0.99   Max: No Debt
Current: No Debt

Equity to Asset 0.76
GERN's Equity to Asset is ranked higher than
79% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GERN: 0.76 )
GERN' s 10-Year Equity to Asset Range
Min: 0.41   Max: 0.96
Current: 0.76

0.41
0.96
F-Score: 4
Z-Score: 2.30
M-Score: 11.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -3149.35
GERN's Operating margin (%) is ranked higher than
53% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. GERN: -3149.35 )
GERN' s 10-Year Operating margin (%) Range
Min: -41916.67   Max: -149.32
Current: -3149.35

-41916.67
-149.32
Net-margin (%) -3093.67
GERN's Net-margin (%) is ranked higher than
52% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. GERN: -3093.67 )
GERN' s 10-Year Net-margin (%) Range
Min: -41504.17   Max: -131.51
Current: -3093.67

-41504.17
-131.51
ROE (%) -28.62
GERN's ROE (%) is ranked higher than
73% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. GERN: -28.62 )
GERN' s 10-Year ROE (%) Range
Min: -157.29   Max: -17.94
Current: -28.62

-157.29
-17.94
ROA (%) -25.89
GERN's ROA (%) is ranked higher than
72% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. GERN: -25.89 )
GERN' s 10-Year ROA (%) Range
Min: -85.77   Max: -14.86
Current: -25.89

-85.77
-14.86
ROC (Joel Greenblatt) (%) -39045.16
GERN's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. GERN: -39045.16 )
GERN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -27405.28   Max: -89.68
Current: -39045.16

-27405.28
-89.68
Revenue Growth (3Y)(%) -20.60
GERN's Revenue Growth (3Y)(%) is ranked higher than
65% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. GERN: -20.60 )
GERN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 58.7
Current: -20.6

0
58.7
EBITDA Growth (3Y)(%) -32.90
GERN's EBITDA Growth (3Y)(%) is ranked higher than
59% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. GERN: -32.90 )
GERN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -35.5   Max: 13.5
Current: -32.9

-35.5
13.5
EPS Growth (3Y)(%) -33.40
GERN's EPS Growth (3Y)(%) is ranked higher than
59% of the 803 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. GERN: -33.40 )
GERN' s 10-Year EPS Growth (3Y)(%) Range
Min: -35.9   Max: 32.5
Current: -33.4

-35.9
32.5
» GERN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

GERN Guru Trades in Q1 2014

John Burbank 25,000 sh (New)
Jean-Marie Eveillard 3,054,252 sh (+46.43%)
Jean-Marie Eveillard 2,013 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2014

GERN Guru Trades in Q2 2014

Jean-Marie Eveillard 3,548,124 sh (+16.17%)
John Burbank 25,000 sh (unchged)
» More
Q3 2014

GERN Guru Trades in Q3 2014

John Burbank 25,000 sh (unchged)
Jean-Marie Eveillard 2,198,124 sh (-38.05%)
» More
Q4 2014

GERN Guru Trades in Q4 2014

Paul Tudor Jones 15,072 sh (New)
Jim Simons 429,880 sh (New)
John Burbank Sold Out
Jean-Marie Eveillard 1,128,866 sh (-48.64%)
» More
» Details

Insider Trades

Latest Guru Trades with GERN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.18
GERN's P/B is ranked higher than
70% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. GERN: 5.18 )
GERN' s 10-Year P/B Range
Min: 1.07   Max: 12.04
Current: 5.18

1.07
12.04
PFCF 28.67
GERN's PFCF is ranked higher than
96% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GERN: 28.67 )
GERN' s 10-Year PFCF Range
Min: 0   Max: 68.23
Current: 28.67

0
68.23
POCF 86.00
GERN's POCF is ranked higher than
90% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GERN: 86.00 )
GERN' s 10-Year POCF Range
Min: 0   Max: 0
Current: 86

EV-to-EBIT -14.50
GERN's EV-to-EBIT is ranked higher than
66% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GERN: -14.50 )
GERN' s 10-Year EV-to-EBIT Range
Min: -16.7   Max: -0.3
Current: -14.5

-16.7
-0.3
Current Ratio 3.67
GERN's Current Ratio is ranked higher than
69% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. GERN: 3.67 )
GERN' s 10-Year Current Ratio Range
Min: 3.67   Max: 21.82
Current: 3.67

3.67
21.82
Quick Ratio 3.67
GERN's Quick Ratio is ranked higher than
71% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. GERN: 3.67 )
GERN' s 10-Year Quick Ratio Range
Min: 3.67   Max: 21.82
Current: 3.67

3.67
21.82
Days Sales Outstanding 304.85
GERN's Days Sales Outstanding is ranked higher than
67% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. GERN: 304.85 )
GERN' s 10-Year Days Sales Outstanding Range
Min: 26.84   Max: 6149.24
Current: 304.85

26.84
6149.24

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.14
GERN's Price/Net Cash is ranked higher than
85% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 103.40 vs. GERN: 6.14 )
GERN' s 10-Year Price/Net Cash Range
Min: 1.7   Max: 119.29
Current: 6.14

1.7
119.29
Price/Net Current Asset Value 6.06
GERN's Price/Net Current Asset Value is ranked higher than
84% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 42.30 vs. GERN: 6.06 )
GERN' s 10-Year Price/Net Current Asset Value Range
Min: 1.64   Max: 70.17
Current: 6.06

1.64
70.17
Price/Tangible Book 5.18
GERN's Price/Tangible Book is ranked higher than
75% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. GERN: 5.18 )
GERN' s 10-Year Price/Tangible Book Range
Min: 1.25   Max: 18.35
Current: 5.18

1.25
18.35
Earnings Yield (Greenblatt) -6.90
GERN's Earnings Yield (Greenblatt) is ranked higher than
63% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. GERN: -6.90 )
GERN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -10.8   Max: 0
Current: -6.9

-10.8
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:GON.Germany,
Geron Corp was incorporated in the State of Delaware on November 28, 1990. It is a clinical stage biopharmaceutical company developing a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in the segment of the discovery and development of therapeutic products for oncology. It owns worldwide commercial rights with U.S. patent coverage extending through 2025 for imetelstat. Its patent rights relating to telomerase cover the cloned genes that encode the RNA component and the catalytic protein component of human telomerase, cells that are immortalized by expression of recombinant hTERT, and cancer diagnostics based on detecting the expression of telomerase in cancer cells. The Company is subject to various and often changing federal, state, local and international laws, rules, regulations, guidelines and recommendations relating to safe working conditions and manufacturing practices.
» More Articles for GERN

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
WEEKLY CFO SELLS HIGHLIGHT: HTM, OVTI, VSEA, KSWS,GERN, ATRC Jun 20 2011 
Geron Corp. Reports Operating Results (10-Q) Oct 29 2010 
Geron: Buyer Beware Oct 13 2010 
Geron Corp. (GERN) President and CEO Thomas Okarma sells 18,874 Shares Jun 03 2010 
Geron Corp. (GERN) EVP and CFO David Greenwood sells 14,746 Shares Jun 03 2010 
Geron Corporation Reports 2009 Second Quarter Financial Results and Events Jul 30 2009 
Geron Corp (GERN): Stock of the Day Mar 10 2009 
Banking 60% on the Day the World Changed: FDA Approves Geron to Test Embryonic Stem Cells on Humans Jan 24 2009 
The Next Boom Emerges Nov 23 2008 


More From Other Websites
Geron to Present at the Bank of America Merrill Lynch Healthcare Conference Apr 27 2015
Geron to Present at the Bank of America Merrill Lynch Healthcare Conference Apr 27 2015
The Zacks Analyst Blog Highlights: Gilead Sciences, Biogen, Geron, Johnson & Johnson and Anthera... Apr 22 2015
Law Offices of Howard G. Smith Announces Investigation of Geron Corporation Apr 21 2015
Oppenheimer Is Excited About These 3 Biotech Stocks Apr 21 2015
Coverage initiated on Geron by Oppenheimer Apr 21 2015
The Zacks Analyst Blog Highlights: Pfizer, Pharmacyclics, Geron, Anthera Pharmaceuticals and Cytori... Apr 16 2015
3 Biotech Stocks Under $10 with Amazing Growth Prospects - Analyst Blog Apr 15 2015
Geron to Present at the 14th Annual Needham Healthcare Conference Apr 07 2015
Geron to Present at the 14th Annual Needham Healthcare Conference Apr 07 2015
Market Has Not Yet Noticed Potential in Geron (GERN); Have You? - Tale of the Tape Apr 07 2015
GERON CORP Financials Mar 18 2015
Biotech bull case: MNK & ICPT Mar 13 2015
Geron Corporation (GERN) Jumps: Stock Rises 5.6% - Tale of the Tape Mar 13 2015
GERON CORP Files SEC form 10-K, Annual Report Mar 11 2015
Geron (GERN) Shares March Higher, Can It Continue? - Tale of the Tape Mar 09 2015
Geron Shares Could Double Mar 05 2015
Geron's Q4 Loss Narrows Y/Y, Announces Restructuring Plan - Analyst Blog Mar 04 2015
Geron reports 4Q loss Mar 03 2015
Geron reports 4Q loss Mar 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK